Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for Rohit M. Desai
30.67
-0.11 (-0.36%)
Jul 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 29.94 - 30.82
52 week 16.91 - 60.52
Open 30.66
Vol / Avg. 529,232.00/836,685.00
Mkt cap 1.14B
P/E 15.28
Div/yield     -
EPS 2.01
Shares 36.75M
Beta 1.81
Inst. own 79%
Aug 23, 2016
Q4 2016 Lannett Company Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2016
Lannett Company Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Lannett Company Inc at Deutsche Bank Health Care Conference
May 3, 2016
Q3 2016 Lannett Company Inc Earnings Call
May 3, 2016
Q3 2016 Lannett Company Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -3.90% 36.87%
Operating margin 13.29% 55.67%
EBITD margin - 57.04%
Return on average assets -1.25% 35.23%
Return on average equity -4.02% 39.56%
Employees 502 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company's products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital products, Ursodiol capsules and pain management products. Levothyroxine Sodium tablets are produced and marketed with around 12 varying potencies. Digoxin tablets are produced and marketed with approximately two different potencies. It distributes around three products containing Butalbital. Ursodiol capsules are produced and marketed in 300 milligram capsules. The Company offers a range of pain management products, such as Cocaine Topical Solution (C-Topical), Morphine Sulfate Oral Solution, Hydromorphone hydrochloric acid (HCl) tablets and Codeine Sulfate tablets.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Arthur P. Bedrosian J.D. Chief Executive Officer, Director
Age: 69
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 63
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 58
Bio & Compensation  - Reuters
Kevin R. Smith Vice President - Sales and Marketing
Age: 55
Bio & Compensation  - Reuters
John M. Abt Vice President of Quality
Age: 50
Bio & Compensation  - Reuters
Mahendra Dedhiya Vice President of Scientific Affairs
Age: 66
Bio & Compensation  - Reuters
Rohit Desai Vice President of New Product Strategy
Age: 74
Bio & Compensation  - Reuters
Albert Paonessa III Director
Age: 55
Bio & Compensation  - Reuters
David Drabik Independent Director
Age: 47
Bio & Compensation  - Reuters